Cabozantinib is a potent, multitargeted tyrosine kinase inhibitor that blocks signaling pathways involved in tumor growth, metastasis, and angiogenesis, including VEGFR, MET, AXL, and RET. It is clinically… Read more


















































Cabozantinib is a potent, multitargeted tyrosine kinase inhibitor that blocks signaling pathways involved in tumor growth, metastasis, and angiogenesis, including VEGFR, MET, AXL, and RET. It is clinically indicated for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, medullary thyroid cancer, and certain differentiated thyroid and neuroendocrine tumors. This category provides essential reference standards for pharmaceutical laboratories engaged in rigorous analytical testing and quality control. The collection includes high-quality Cabozantinib API, along with a broad range of related compounds such as process-related impurities, degradation products, metabolites, and stable isotope labelled standards. These materials are critical for accurate impurity profiling, supporting forced degradation studies, and facilitating robust method validation. Laboratories utilize these structurally confirmed reference standards to ensure compliance with global regulatory guidelines, enabling precise quantification and reliable genotoxicity screening during the development and stability testing of pharmaceutical dosage forms.